المؤلفون: M. M. Tsyganov, I. A. Tsydenova, V. A. Markovich, M. K. Ibragimova, E. O. Rodionov, S. A. Tuzikov, N. V. Litvyakov, М. М. Цыганов, И. А. Цыденова, В. А. Маркович, М. К. Ибрагимова, Е. О. Родионов, С. А. Тузиков, Н. В. Литвяков

المصدر: Advances in Molecular Oncology; Том 9, № 4 (2022); 78‑88 ; Успехи молекулярной онкологии; Том 9, № 4 (2022); 78‑88 ; 2413-3787 ; 2313-805X ; 10.17650/2313-805X-2022-9-4

مصطلحات موضوعية: экспрессия, carcinomatosis, genes of the ABC transporter family, chemosensitivity genes, tumor heterogeneity, expression, канцероматоз, гены семейства ABC-транспортеров, гены химиочувствительности, гетерогенность опухоли

وصف الملف: application/pdf

العلاقة: https://umo.abvpress.ru/jour/article/view/479/283Test; Smyth E.C., Nilsson M., Grabsch H.I. et al. Gastric cancer. Lancet 2020;396(10251):635–48. DOI:10.1016/s0140-6736(20)31288-5; Bhatia S., Frangioni J.V., Hoffman R.M. et al. The challenges posed by cancer heterogeneity. Nat Biotechnol 2012;30(7):604–10. DOI:10.1038/nbt.2294; Pectasides E., Stachler M.D., Derks S. et al. Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma. Cancer Discov 2018;8(1):37–48. DOI:10.1158/2159-8290.cd-17-0395; Gullo I., Carneiro F., Oliveira C., Almeida G.M. Heterogeneity in gastric cancer: from pure morphology to molecular classifications. Pathobiology 2018;85(1–2):50–63. DOI:10.1159/000473881; Marusyk A., Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 2010;1805(1):105–17. DOI:10.1016/j.bbcan.2009.11.002; De Aretxabala X., Yonemura Y., Sugiyama K. et al. Gastric cancer heterogeneity. Cancer 1989;63(4):791–8. DOI:10.1002/1097-0142(19890215)63:43.0.co;2-w; Amato M., Perrone G., Righi D. et al. HER2 status in gastric cancer: comparison between primary and distant metastatic disease. Pathol Oncol Res 2017;23(1):55–61. DOI:10.1007/s12253-016-0082-5; Cho E.Y., Park K., Do I. et al. Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas. Mod Pathol 2013;26(5):677–84. DOI:10.1038/modpathol.2012.205; Silva A.N., Coffa J., Menon V. et al. Frequent coamplification of receptor tyrosine kinase and downstream signaling genes in Japanese primary gastric cancer and conversion in matched lymph node metastasis. Ann Surg 2018;267(1):114–21. DOI:10.1097/SLA.0000000000002042; Zhou K.I., Peterson B., Serritella A. et al. Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy. Clin Cancer Res 2020;26(24):6453–63. DOI:10.1158/1078-0432.CCR-20-2085.; Robey R.W., Pluchino K.M., Hall M.D. et al. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer 2018;18(7): 452–64. DOI:10.1038/s41568-018-0005-8; Liu X. ABC family transporters, in drug transporters in drug disposition, effects and toxicity. Adv Exp Med Biol 2019;1141(1):13–100. DOI:10.1007/978-981-13-7647-4_5; Amawi H., Sim H.-M., Tiwari A.K. et al. ABC family transporters, in drug transporters in drug disposition, effects and toxicity. Adv Exp Med Biol 2019;1141(1):549–80. DOI:10.1007/978-981-13-7647-4_5; Tsyganov M.M., Freidin M.B., Ibragimova M.K. et al. Genetic variability in the regulation of the expression cluster of MDR genes in patients with breast cancer. Cancer Chem Pharmacol 2017;80(2):251–60. DOI:10.1007/s00280-017-3354-1; Mao X., He Z., Zhou F. et al. Prognostic significance and molecular mechanisms of adenosine triphosphate-binding cassette subfamily C members in gastric cancer. Medicine (Baltimore) 2019;98(50):1–12. DOI:10.1097/MD.0000000000018347; Araújo T., Seabra A., Lima E. et al. Recurrent amplification of RTEL1 and ABCA13 and its synergistic effect associated with clinicopathological data of gastric adenocarcinoma. Mol Cytogenet 2016;9(1):1–7. DOI:10.1186/s13039-016-0260-x; Tsyganov M., Rodionov E., Miller S. et al. Substantiation of expressive markers use to personalize lung cancer chemotherapy. Antibiot Khimioter 2015;60(9–10):38–45.; Wei K.-K., Jiang L., Wei Y.-Y. et al. The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis. Tumor Biol 2014;35(9):8721–31. DOI:10.1007/s13277-014-2128-1; Chen W., Wang J., Li X. et al. Prognostic significance of BRCA1 expression in gastric cancer. Med Oncol 2013;30(1):1–6. DOI:10.1007/s12032-012-0423-5; Huang J., Hu H., Xie Y. et al. Effect of TUBB3, TS and ERCC1 mRNA expression on chemoresponse and clinical outcome of advanced gastric cancer by multiplex branched-DNA liquid chip technology. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2013;38(6): 582–9. (In Chinese). DOI:10.3969/j.issn.1672-7347.2013.06.006; Schwartz G.F., Hortobagyi G.N. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26–28, 2003, Philadelphia, Pennsylvania. Cancer 2004;10(4):273–94. DOI:10.1002/cncr.20298; Pfaffl M.W. A new mathematical model for relative quantification in real-time RT–PCR. Nucleic Acids Res 2001;29(9):e45. DOI:10.1093/nar/29.9.e45; Sung J.-Y., Shin H.-T., Sohn K.-A. et al. Assessment of intratumoral heterogeneity with mutations and gene expression profiles. PLoS One 2019;14(7):1–15. DOI:10.1371/journal.pone.0219682; Gyanchandani R., Lin Y., Lin H.-M. et al. Intratumor heterogeneity affects gene expression profile test prognostic risk stratification in early breast cancer. Clin Cancer Res 2016;22(21):5362–9. DOI:10.1158/1078-0432.CCR-15-2889; Tober J.M., Halske C., Behrens H.-M. et al. Intratumoral heterogeneity and loss of ARID1A expression in gastric cancer correlates with increased PD-L1 expression in Western patients. Hum Pathol 2019;94(1):98–109. DOI:10.1016/j.humpath.2019.09.016; Durbecq V., Paesmans M., Cardoso F. et al. Topoisomerase-IIα expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther 2004;3(10):1207–14. DOI:10.1158/1535-7163.1207.3.10; De Oliveira J., Felipe A.V., Neto R.A. et al. Association between ABCB1 immunohistochemical expression and overall survival in gastric cancer patients. Asian Pac J Cancer Prevent 2014;15(16):6935–8. DOI:10.7314/apjcp.2014.15.16.6935; Zhang G., Wang Z., Qian F. et al. Silencing of the ABCC4 gene by RNA interference reverses multidrug resistance in human gastric cancer. Oncol Rep 2015;33(3):1147–54. DOI:10.3892/or.2014.3702; Zhu C.-Y., Lv Y.-P., Yan D.-F. et al. Knockdown of MDR1 increases the sensitivity to adriamycin in drug resistant gastric cancer cells. Asian Pac J Cancer Prev 2013;14(11):6757–60. DOI:10.7314/apjcp.2013.14.11.6757; Li S.-C., Ma R., Wu J.-Z. et al. Delineation of gastric cancer subtypes by co-regulated expression of receptor tyrosine kinases and chemosensitivity genes. Am J Transl Res 2015;7(8):1429–39.; Cao Y., Zhang G., Wang P. et al. Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer. BMC Gastroenterol 2017;17(1):1–13. DOI:10.1186/s12876-016-0561-x; Terashima M., Ichikawa W., Ochiai A. et al. TOP2A, GGH, and PECAM1 are associated with hematogenous, lymph node, and peritoneal recurrence in stage II/III gastric cancer patients enrolled in the ACTS-GC study. Oncotarget 2017;8(34):57574–82. DOI:10.18632/oncotarget.15895; Tsyganov M.M., Rodionov E.O., Ibragimova M.K. et al. Personalized prescription of chemotherapy based on assessment of mRNA expression of BRCA1, RRM1, ERCC1, TOP1, TOP2α, TUBβ3, TYMS, and GSTP1 genes in tumors compared to standard chemotherapy in the treatment of non-small-cell lung cancer. J Personal Med 2022;12(10):1647.; Tsyganov M.M., Ibragimova M.K., Gaptulbarova K.A. et al. DNA Copy number aberrations and expression of ABC transporter genes in breast tumour: correlation with the effect of neoadjuvant chemotherapy and prognosis of the disease. Pharmaceutics 2022;14(5):1–19. DOI:10.3390/pharmaceutics14050948; Tsyganov M.M., Ibragimova M.K., Garbukov E.Y. et al. Predictive and prognostic significance of mRNA Expression and DNA copies aberrations of ERCC1, RRM1, TOP1, TOP2A, TUBB3, TYMS, and GSTP1 genes in patients with breast cancer. Diagnostics 2022;12(2):1–15. DOI:10.3390/diagnostics12020405; Moiseyenko V.M., Volkov N.M., Suspistin E.N. et al. Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer. Med Oncol 2013;30(2):1–9. DOI:10.1007/s12032-013-0545-4; https://umo.abvpress.ru/jour/article/view/479Test

الإتاحة: https://doi.org/10.17650/2313-805X-2022-9-4-78-88Test
https://doi.org/10.17650/2313-805X-2022-9-4Test
https://doi.org/10.1016/s0140-6736Test(20)31288-5
https://doi.org/10.1038/nbt.2294Test
https://doi.org/10.1158/2159-8290.cd-17-0395Test
https://doi.org/10.1159/000473881Test
https://doi.org/10.1016/j.bbcan.2009.11.002Test
https://doi.org/10.1002/1097-0142Test(19890215)63:4<791::aidcncr2820630431>3.0.co;2-w
https://doi.org/10.1007/s12253-016-0082-5Test
https://doi.org/10.1038/modpathol.2012.205Test

المؤلفون: L. Laletina A., N. Moiseeva I., D. Klimova A., A. Stavrovskaya A., Л. Лалетина А., Н. Моисеева И., Д. Климова А., А. Ставровская А.

المساهمون: E.Yu. Rybalkina, N.N. Kalitin, Е.Ю. Рыбалкина, Н.Н. Калитин

المصدر: Advances in Molecular Oncology; Том 6, № 1 (2019); 49-56 ; Успехи молекулярной онкологии; Том 6, № 1 (2019); 49-56 ; 2413-3787 ; 2313-805X ; 10.17650/2313-805X-2019-6-1

مصطلحات موضوعية: bortezomib, multiple myeloma, multidrug resistance, ABC-transporter, YB-1, P-glycoprotein, MRP1, BCRP, MVP, бортезомиб, множественная миелома, множественная лекарственная устойчивость, АВС-транспортер, Р-гликопротеин

وصف الملف: application/pdf

العلاقة: https://umo.abvpress.ru/jour/article/view/206/174Test; Бессмельцев С.С. Множественная миелома (патогенез, клиника, диагностика, дифференциальный диагноз). Клиническая онкогематология 2013;6(3):237—57.; Moreau P., San Miguel J., Sonneveld P. et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(suppl 4):iv52-61. DOI:10.1093/annonc/mdx096. PMID: 28453614.; Ставровская А.А., Генс Г.П. Некоторые новые аспекты исследований множественной лекарственной устойчивости опухолевых клеток. Успехи молекулярной онкологии 2014;(1):5—11.; Robey R., Pluchino K., Hall M. et al. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer 2018;18(7):452—64. DOI:10.1038/s41568-018-0005-8. PMID: 29643473.; Елисеева И.А., Ким Е.Р., Гурьянов С.Г. и др. Y-бокс-связывающий белок 1 (YB-1) и его функции. Успехи биологической химии 2011;51:65-132.; Lasham A., Print C.G, Woolley A.G. et al. YB-1: oncoprotein, prognostic marker and therapeutic target. Biochem J 2013;449(1):11—23. DOI:10.1042/bj20121323. PMID: 23216250.; Stein U., Jurchott K., Walther W. et al. Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters. J BiolChem 2001;276(30):28562—9. DOI:10.1074/jbc.m100311200. PMID: 11369762.; Stein U., Bergmann S., Scheffer G.L. et al. YB-1 facilitates basal and 5-fluorouracil-inducible expression of the human major vault protein (MVP) gene. Oncogene 2005;24(22):3606—18. DOI:10.1038/sj.onc.1208386. PMID:15750632.; Wiberg K., Carlson K., Aleskog A. et al. In vitro activity of bortezomib in cultures of patient tumour cells-potential utility in haematological malignancies. Med Oncol 2009;26(2):193—201. DOI:10.1007/s12032-008-9107-6. PMID: 19016012.; Панищева Л.А., Какпакова Е.С., Рыбалкина Е.Ю., Ставровская А.А. Влияние протеасомного ингибитора бортезомиба на экспрессию генов множественной лекарственной устойчивости и активность киназы. Биохимия 2011;76(9):1238—47.; Scheffer G.L., Schroeijers A.B., Izquierdo M.A. et al. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 2000;12(6):550—6. DOI:10.1097/00001622-200011000-00007. PMID: 11085454.; Wang H., Wang X., Li Y. et. al. The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi¬drug resistance through the NF-kappaB pathway. Pharmazie 2012;67(2):187—92. PMID: 22512091.; Hu Y., Wang L., Wang L. et. al. Preferential cytotoxicity of bortezomib toward highly malignant human liposarcoma cells via suppression of MDR1 expression and function. Toxicol Appl Pharmacol 2015;283(1):1—8. DOI:10.1016/j.taap.2014.12.015. PMID: 25576094.; Черных Ю.Б., Голенков А.К., Шушанов С.С. Влияние экспрессии генов множественной лекарственной устойчивости на клиническое течение множественной миеломы. Альманах клинической медицины 2016;44(5):624—30.; Schwarzenbach H. Expression of MDR1/ P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma. Medical Oncology 2002;19(2):87—104. DOI:10.1385/mo:19:2:87. PMID: 11085454.; Izquierdo M.A., van der Zee A.G., Vermorken J.B. et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995;87(16):1230—7. DOI:10.1093/jnci/87.16.1230. PMID: 7563169.; Arts H.J., Katsaros D., de Vries E.G. et al. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res 1999;5(10):2798—805. PMID: 10537344.; Oda Y., Ohishi Y., Basaki Y. et al. Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/ MVP and P-glycoprotein expression. Cancer Sci 2007;98(7):1020—6. DOI:10.1111/j.1349-7006.2007.00492.x. PMID: 17459055.; Balsas P., Galan-Malo P., Marzo I. et al. Bortezomib resistance in a myeloma cell line is associated to PSMp5 overexpression and polyploidy. Leuk Res 2012;36(2):212—8. DOI:10.1016/j.leukres.2011.09.011. PMID: 21978467.; Franke N.E., Kaspers G.L., Berg N. et al. Acquired resistance to bortezomib in human RPMI8226 multiple myeloma cells: molecular characterization, cross-resistance with other proteasome inhibitors but marked sensitization to glucocorticoids. Blood 2008;112:2640.; Kim K.H., Cheong H.J., Lee M.Y. et al. Bortezomib is more effective to side population of RPMI8226 myeloma cells than classical anti-myeloma agents. Anticancer Res 2019;39(1):127–33. DOI:10.21873/anticanres.13088. PMID: 30591449.; Park J., Bae E.K. Lee C. et al. Establishment and characterization of bortezomib-resistant U266 cell line: constitutive activation of NF-κB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis. BMB Rep 2014;47(5):274–9. PMID: 24286313.; https://umo.abvpress.ru/jour/article/view/206Test

الإتاحة: https://doi.org/10.17650/2313-805X-2019-6-1-49-56Test
https://doi.org/10.17650/2313-805X-2019-6-1Test
https://doi.org/10.1093/annonc/mdx096Test
https://doi.org/10.1038/s41568-018-0005-8Test
https://doi.org/10.1042/bj20121323Test
https://doi.org/10.1074/jbc.m100311200Test
https://doi.org/10.1038/sj.onc.1208386Test
https://doi.org/10.1007/s12032-008-9107-6Test
https://doi.org/10.1097/00001622-200011000-00007Test
https://doi.org/10.1016/j.taap.2014.12.015Test